Immunoglobulin E (IgE) specific for Ambrosia trifida pollen allergens (IgE (Amb t))

Immunoglobulin E (IgE) antibodies specific for Ambrosia trifida (Giant Ragweed) pollen allergens are central components of the type I hypersensitivity response in sensitized individuals (National Institute of Allergy and Infectious Diseases, "Ragweed Allergy"). These antibodies are produced in response to allergens such as Amb t 1, the primary protein allergen found in Giant Ragweed pollen (WHO/IUIS Allergen Nomenclature Sub-Committee, 2024). When an individual is re-exposed to the pollen, the allergens cross-link the specific IgE molecules bound to high-affinity FcεRI receptors on mast cells and basophils. This cross-linking triggers the immediate release of inflammatory mediators, including histamine, prostaglandins, and leukotrienes, which cause the symptoms of allergic rhinitis and asthma (StatPearls, "Type I Hypersensitivity"). Clinically, these IgE antibodies serve as both a diagnostic marker and a therapeutic target. Drugs like Omalizumab work by binding to the constant region of free IgE, thereby preventing it from attaching to its receptors and inhibiting the allergic cascade (PubChem, CID 16131215). Additionally, allergen-specific immunotherapy (AIT) utilizes extracts of Ambrosia trifida to desensitize the immune system, shifting the response from an IgE-mediated allergic reaction to a more tolerant state often involving IgG4 antibodies (American Academy of Allergy, Asthma & Immunology, "Allergen Immunotherapy").

Other names

Giant ragweed-specific IgEAmbrosia trifida-specific IgEAnti-Amb t IgERagweed-specific IgE

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (PubChem, CID 16131215). Allergen-specific immunotherapy (AIT) involves the administration of Ambrosia trifida allergens to induce immune tolerance, leading to the production of IgG4 blocking antibodies and the suppression of IgE-mediated mast cell activation (American Academy of Allergy, Asthma & Immunology, "Allergen Immunotherapy").